Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors

Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors

Bibliographic Details
Main Authors:	Sasaki, Koji, Strom, Sara S., O’Brien, Susan, Jabbour, Elias, Ravandi, Farhad, Konopleva, Marina, Borthakur, Gautam, Pemmaraju, Naveen, Daver, Naval, Jain, Preetesh, Pierce, Sherry, Kantarjian, Hagop, Cortes, Jorge E.
Format:	Online
Language:	English
Published:	2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884053/

Similar Items

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
by: DiNardo, Courtney D, et al.
Published: (2015)

Extramedullary Acute Myeloid Leukemia: Leukemic Pleural Effusion, Case Report and Review of the Literature
by: Pemmaraju, Naveen, et al.
Published: (2014)

Suboptimal Responses in Chronic Myeloid Leukemia
by: Jabbour, Elias, et al.
Published: (2012)

A Single Case of Rosai–Dorfman Disease Marked by Pathologic Fractures, Kidney Failure, and Liver Cirrhosis Treated with Single-Agent Cladribine
by: Sasaki, Koji, et al.
Published: (2014)

Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature
by: Pemmaraju, Naveen, et al.
Published: (2015)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
by: Hochhaus, Andreas, et al.
Published: (2013)

The changing face of acute myeloid leukemia therapeutics in the elderly population
by: Daver, Naval, et al.
Published: (2015)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
by: Takahashi, Koichi, et al.
Published: (2016)

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy
by: DiNardo, CD, et al.
Published: (2014)

Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine
by: Badar, Talha, et al.
Published: (2015)

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia
by: Nazha, Aziz, et al.
Published: (2013)

Overview of recent developments in chronic lymphocytic leukemia
by: Jain, Preetesh, et al.
Published: (2012)

Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034
by: Shah, Neil P., et al.
Published: (2016)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
by: Brümmendorf, Tim H., et al.
Published: (2015)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
by: Gambacorti-Passerini, Carlo, et al.
Published: (2014)

Acute Myeloid Leukemia as a Model for Cancer Therapy
by: Ravandi, Farhad
Published: (2012)

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center
by: Walter, Roland B., et al.
Published: (2014)

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells
by: Carter, Bing Z., et al.
Published: (2015)

Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics
by: Mayer, Jiří, et al.
Published: (2014)

Successful treatment of aplastic anemia–paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation
by: Sasaki, Koji, et al.
Published: (2016)

Invisible Mycosis Fungoides: Not to be Missed in Chronic Pruritus
by: Deen, Kristyn, et al.
Published: (2015)

Primary gastric chorioadenocarcinoma: a needle in a haystack
by: Shastri, Aditi, et al.
Published: (2011)

Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
by: Chen, Z, et al.
Published: (2016)

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses
by: Wetzler, M, et al.
Published: (2015)

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
by: Gambacorti‐Passerini, Carlo, et al.
Published: (2015)

The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era
by: Renault, Ilana Zalcberg, et al.
Published: (2011)

Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes
by: Sherry, Barbara, et al.
Published: (2015)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
by: Xu, Zhenshu, et al.
Published: (2009)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
by: Barak, Avital F., et al.
Published: (2011)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
by: Perrotti, Danilo, et al.
Published: (2012)

Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
by: DeAngelo, D J
Published: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
by: Haznedaroğlu, İbrahim C.
Published: (2013)

Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
by: Wieczorek, Agnieszka, et al.
Published: (2016)

L-tyrosine improves neuroendocrine function in a mouse model of chronic stress
by: Wang, Zhihua, et al.
Published: (2012)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
by: Loghavi, Sanam, et al.
Published: (2014)

Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia
by: Jelinek, Jaroslav, et al.
Published: (2011)

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
by: Oliver Ottmann, et al.
Published: (2018-09-01)

Using 2nd generation tyrosine kinase inhibitors in frontline management of chronic phase chronic myeloid leukemia
by: Jayakar, Vishal
Published: (2014)

Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and Management
by: Bauer,1, Stephanie, et al.
Published: (2016)

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells
by: Shi, Ping, et al.
Published: (2010)